Valuation: CROSSJECT

Market Cap 82.43M 94.93M 76.85M 70.6M 134M 9.03B 135M 906M 354M 4.51B 356M 349M 14.96B P/E 2026 *
3.69x
P/E 2027 * 2.91x
Enterprise Value 64.53M 74.32M 60.16M 55.27M 105M 7.07B 106M 709M 277M 3.53B 279M 273M 11.71B EV / Sales 2026 *
1.06x
EV / Sales 2027 * 0.84x
Free-Float
90.34%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 63 2001-08-07
Director of Finance/CFO - 2026-03-24
Corporate Officer/Principal - 2024-08-19
Director TitleAgeSince
Chairman 67 2009-06-25
Director/Board Member 67 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.20%+11.56%-34.72%-55.96% 104M
-0.48%+4.02%+92.79%+10.53% 80.44M
Average -0.56%+8.64%+29.04%-22.72% 92.45M
Weighted average by Cap. -0.58%+9.38%+20.76%-27.03%

Financials

2026 *2027 *
Net sales 60.8M 70.02M 56.69M 52.08M 98.49M 6.66B 99.57M 668M 261M 3.33B 263M 257M 11.03B 42.3M 48.72M 39.44M 36.23M 68.52M 4.63B 69.27M 465M 182M 2.32B 183M 179M 7.68B
Net income 28.3M 32.59M 26.39M 24.24M 45.84M 3.1B 46.35M 311M 122M 1.55B 122M 120M 5.14B 7.75M 8.93M 7.23M 6.64M 12.55M 849M 12.69M 85.19M 33.3M 424M 33.52M 32.78M 1.41B
Net Debt -17.9M -20.61M -16.69M -15.33M -29M -1.96B -29.31M -197M -76.92M -980M -77.42M -75.72M -3.25B -47M -54.13M -43.82M -40.26M -76.14M -5.15B -76.97M -517M -202M -2.57B -203M -199M -8.53B
Logo CROSSJECT
Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-